slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Reservoir Based Drug Delivery The CoStar ™ System and Beyond PowerPoint Presentation
Download Presentation
Reservoir Based Drug Delivery The CoStar ™ System and Beyond

Loading in 2 Seconds...

play fullscreen
1 / 18

Reservoir Based Drug Delivery The CoStar ™ System and Beyond - PowerPoint PPT Presentation

  • Uploaded on

Reservoir Based Drug Delivery The CoStar ™ System and Beyond. Jeff Shanley Founder and Chief Technology Officer. Conflicts. Founder and Chief Technology Officer Conor Medsystems, Inc. CoStar ™ Cobalt Chromium Stent. Bridge Elements. Reservoirs with Bioresorbable Polymers.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Reservoir Based Drug Delivery The CoStar ™ System and Beyond' - miller

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Reservoir Based Drug Delivery

The CoStar™ System and Beyond

Jeff Shanley

Founder and Chief Technology Officer

  • Founder and Chief Technology Officer
    • Conor Medsystems, Inc.

CoStar™ Cobalt Chromium Stent

Bridge Elements

Reservoirs with

Bioresorbable Polymers

Ductile Hinges

reservoir based drug delivery
Reservoir Based Drug Delivery

Reservoirs are:

  • Non Deforming – materials versatility
  • Deep – structure and directionality
  • Protective – against mechanical and biochemical damage
  • Minimize tissue/polymer contact area

Programmable Loading: Multiple Drugs with

Independent Release Kinetics and Directions

pimecrolimus eluting stent
Pimecrolimus Eluting Stent
  • Inflammation is thought to play a central role in restenosis
  • Pimecrolimus is a potent anti-inflamatory agent (but not an MTOR inhibitor)
  • A Dual Release-Mode Inlay was developed
    • Higher drug release rate in first several days (peak inflamatory response period)
    • Lower rate, linear release over extended period
  • 100% resorption of both drug and polymer
dual drug program combine 2 agents for restenosis prevention
Dual Drug Program: Combine 2 Agents for Restenosis Prevention
  • Attack different pathways, e.g.:
    • Anti-inflammatory (pimecrolimus)
    • Anti-mitotic (paclitaxel)
  • Completely independent dose and release kinetics
    • Different polymers and formulations
    • PTX: 11 μg, extended release
    • PLS: 160 μg, dual release-mode
  • Complete resorption of all drugs and polymers (late thrombosis)
dual pimecrolimus paclitaxel eluting stent
Dual Pimecrolimus / Paclitaxel Eluting Stent



160 μg Pimecrolimus and 11 μg Paclitaxel

the genesis trial
The Genesis Trial
  • Both the Pimecrolimus Eluting stent and the Dual paclitaxel / pimecrolimus eluting stent will be evaluated in Conor’s upcoming Genesis clinical trial

Myocardial Preservation

Vascular Drug Delivery – Acute MI

Mural Drug Elution For Restenosis

+Luminal DrugElution For Myocardium



target insulin release kinetics
Target Insulin Release Kinetics
  • Target Insulin doses and release rates were estimated from infusion rates reported in the ECLA GIK pilot studies.
more complex inlays for combinations of water soluble and lipid soluble drugs
More complex inlays for combinations of water soluble and lipid soluble drugs
  • Hydrophobic outer layers to control direction and rate of insulin release
  • Discrete Hydrophilic inner matrix forms protective microenvironment for insulin
  • Lipophilic Pimecrolimus inlay added to mural side as anti-restenotic agent
  • Pre-clinical research program is underway




drug eluting absorbable metal stent
Drug Eluting, Absorbable Metal Stent
  • An effective, bio-absorbable stent that “disappears,” leaving a healthy artery is a sought after device.
  • Biotronik has developed a bio-absorbable magnesium alloy for use in stenting
  • Surface Coatings may interfere with the metal resorption process
  • Migration of stent degradation biproducts through a coating may harm drug
  • A “Conorized” Reservoir based AMS is under development for drug delivery
ams 1 release kinetics in plasma
AMS-1 Release Kinetics in Plasma

Total drug load = 440 µg

  • Programmable, Reservoir based DES systems provide potential opportunities to improve efficacy and to expand indications for DES
  • The combination of fully erodable polymers with new classes of drugs and combinations of drugs can now be studied in clinical trials
  • DES indications ‘beyond restenosis’ are technically feasible and pre-clinical work is underway